GeNeuro Reports 2020 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2020 at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2020 and provided a corporate update. https://geneuro.ch/data/news/GeNeuro-PR-1H2020-Results-ENG.pdf